TickerFacts.

Humacyte, Inc. (HUMA): Revenue

Annual figures by period end, from SEC filings.

$2.04M
Year ended 2025-12-31
$2.12M
Trailing 12 months to 2026-06-30
2024-12-31: $02025-12-31: $2.04M$2.04M
2024-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$2.04Mn/a2026-03-27, From 2025-01-01
2024-12-31$0n/a2026-03-27, From 2024-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Humacyte, Inc. (HUMA)2025-12-31$2.04Mn/a
Aligos Therapeutics, Inc. (ALGS)2025-12-31$2.19M-39.5%
Outlook Therapeutics, Inc. (OTLK)2025-09-30$1.41Mn/a
Dyadic International Inc (DYAI)2025-12-31$3.09M-11.6%
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$1.31M+99.2%
Inhibrx Biosciences, Inc. (INBX)2025-12-31$1.30M+550.0%
Surrozen, Inc. (SRZN)2025-12-31$3.48M-67.4%
CRISPR Therapeutics AG (CRSP)2025-12-31$3.51M-90.6%
CG Oncology, Inc. (CGON)2025-12-31$4.04M+254.7%

Compare HUMA, ALGS, OTLK, DYAI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗